Skip to main content
Premium Trial:

Request an Annual Quote

Strengthening its Regulatory Strategy Support, Illumina Buys Myraqa

NEW YORK (GenomeWeb) – Illumina today announced it has acquired regulatory and quality consulting firm Myraqa for an undisclosed amount.

Based in Redwood Shores, Calif., Myraqa was founded in 1998 and specializes in in vitro diagnostics, particularly companion diagnostics, and focuses on regulatory strategy and application support, including premarket approvals, pre-submissions, investigational device exemptions, 510(k)s, de novo 510(k)s, and European Union technical files, Illumina said.

The acquisition comes amid plans by Illumina to push into the clinical space and regulated markets. Earlier this year, the company launched the VeriSeq pre-implantation genetic screening test on the MiSeq platform. While it did not have to go through the US Food and Drug Administration clearance process to launch VeriSeq as a clinical test, because neither the FDA nor the EU regulates the preconception space, Illumina would need to gain regulatory clearance in certain other geographies, including China, to launch the test in those locations.

Also, Illumina has said that it is in the process of developing oncology panels for FDA clearance and that it plans to submit the Verifi non-invasive prenatal test to the FDA for in vitro diagnostic clearance on the HiSeq 2500 by the end of 2014.

The Myraqa acquisition "will bolster Illumina's in-house capabilities for clinical readiness and help prepare [the firm] for its next growth phase in regulated markets," Illumina said in a statement. Myraqa Founder and CEO Mya Thomae will become the vice president of regulatory affairs at Illumina and report to Illumina CMO Rick Klausner, who said that Myraqa will complete its existing programs and continue working with "selected third-parties" on sequencing-based projects.

"With Myraqa, Illumina will continue to pave the way for the use of genomic technology, including next-generation sequencing, in regulated markets while also driving standards for use in the clinic," Klausner said, adding Thomae "will lead Illumina's regulatory strategy and execution, providing us with a world-class regulatory organization … making Illumina a pre-eminent clinical company."

Illumina said that the impact of the deal was included in the 2014 guidance that the company provided in April in its first-quarter financial earnings announcement. At the time, it increased its 2014 guidance and said that revenues for the year were anticipated to grow 21 percent to 23 percent year over year, compared to its previous estimate of 15 percent to 17 percent growth.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.